Kyowa Hakko Kirin Korea Co. released 'Neulasta’ for the treatment of febrile neutropenia
Kyowa Hakko Kirin Korea Co. received insurance drug price of 'Neulasta prefilled syringe inj.(nonproprietary name: pegfilgrastim)' which suppresses the expression of 'febrile neutropenia' in patients with cytotoxic chemotherapy for malignant tumor in 2013 Nov, and entered into...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
